TY - JOUR
T1 - Onset of Mild Cognitive Impairment in Parkinson Disease
AU - Johnson, David K.
AU - Langford, Zachary
AU - Garnier-Villarreal, Mauricio
AU - Morris, John C.
AU - Galvin, James E.
N1 - Funding Information:
Data collection was supported by National Institute on Aging Grants P01 AG03991 and P50 AG05681 (J.C.M.). Data analyses were supported by grants from the National Institute on Aging R01 AG040211, Michael J Fox Foundation, and Morris and Alma Schapiro Fund (J.E.G.).
Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Objective: Characterize the onset and timing of cognitive decline in Parkinson disease (PD) from the first recognizable stage of cognitively symptomatic PD-mild cognitive impairment (PD-MCI) to PD dementia (PDD). Thirty-nine participants progressed from PD to PDD and 25 remained cognitively normal. Methods: Bayesian-estimated disease-state models described the onset of an individual's cognitive decline across 12 subtests with a change point. Results: Subtests measuring working memory, visuospatial processing ability, and crystalized memory changed significantly 3 to 5 years before their first nonzero Clinical Dementia Rating and progressively worsened from PD to PD-MCI to PDD. Crystalized memory deficits were the hallmark feature of imminent conversion of cognitive status. Episodic memory tasks were not sensitive to onset of PD-MCI. For cognitively intact PD, all 12 subtests showed modest linear decline without evidence of a change point. Conclusions: Longitudinal disease-state models support a prodromal dementia stage (PD-MCI) marked by early declines in working memory and visuospatial processing beginning 5 years before clinical diagnosis of PDD. Cognitive declines in PD affect motor ability (bradykinesia), working memory, and processing speed (bradyphrenia) resulting in PD-MCI where visuospatial imagery and memory retrieval deficits manifest before eventual development of overt dementia. Tests of episodic memory may not be sufficient to detect and quantify cognitive decline in PD.
AB - Objective: Characterize the onset and timing of cognitive decline in Parkinson disease (PD) from the first recognizable stage of cognitively symptomatic PD-mild cognitive impairment (PD-MCI) to PD dementia (PDD). Thirty-nine participants progressed from PD to PDD and 25 remained cognitively normal. Methods: Bayesian-estimated disease-state models described the onset of an individual's cognitive decline across 12 subtests with a change point. Results: Subtests measuring working memory, visuospatial processing ability, and crystalized memory changed significantly 3 to 5 years before their first nonzero Clinical Dementia Rating and progressively worsened from PD to PD-MCI to PDD. Crystalized memory deficits were the hallmark feature of imminent conversion of cognitive status. Episodic memory tasks were not sensitive to onset of PD-MCI. For cognitively intact PD, all 12 subtests showed modest linear decline without evidence of a change point. Conclusions: Longitudinal disease-state models support a prodromal dementia stage (PD-MCI) marked by early declines in working memory and visuospatial processing beginning 5 years before clinical diagnosis of PDD. Cognitive declines in PD affect motor ability (bradykinesia), working memory, and processing speed (bradyphrenia) resulting in PD-MCI where visuospatial imagery and memory retrieval deficits manifest before eventual development of overt dementia. Tests of episodic memory may not be sufficient to detect and quantify cognitive decline in PD.
KW - Alzheimer disease
KW - Bayes theorem
KW - Parkinson disease with dementia
KW - Parkinson disease/Parkinsonism
KW - longitudinal
KW - piecewise regression
UR - http://www.scopus.com/inward/record.url?scp=84973098817&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000088
DO - 10.1097/WAD.0000000000000088
M3 - Article
C2 - 25850732
AN - SCOPUS:84973098817
SN - 0893-0341
VL - 30
SP - 127
EP - 133
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 2
ER -